Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited announced the availability of ILUMYA (tildrakizumab) Pen, a self-administered auto-injector treatment option for adults living with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The ILUMYA Pen was engineered to meet the needs of patients with moderate-to-severe plaque psoriasis. Its three-month dosing schedule, combined with the convenience of a self-administered auto-injector Pen supports patient adherence and quality of life, without requiring significant lifestyle adjustments.ii,iii The ILUMYA Pen is also stable at room temperature for 30 days, further simplifying treatment logistics and supporting adherence.ii Data shows that over 93% of patients were successful in using the ILUMYA Pen, following instructions.iv.
Plaque psoriasis affects approximately 80-90% of psoriasis patients and is characterized by red, scaly, and often itchy skin plaques that can significantly impact daily life.vi It affects between half a million to one million Canadians,v with moderate-to-severe plaque psoriasis affecting about 35% of those patients. ILUMYA is an IL-23p19 inhibitor and has shown durable efficacy and a favourable safety profile over five years of study. In pooled analyses from the reSURFACE 1 and 2 trials, nearly 90% of patients on the 100 mg dose maintained their response through Year 5.i The treatment was well-tolerated, with the most common adverse events occurring more frequently than placebo being upper respiratory infections (15.1% vs.
12.3%), injection site reactions (3.9% vs. 2.6%), and headache (3.2% vs. 2.9%).
